News | February 04, 2022
Lupin Q3FY22 PAT at Rs 545.52 cr.
Lupin has reported consolidated financial results for the period ended December 31, 2021
Lupin has reported consolidated financial results for the period ended December 31, 2021
FDA changes inspection classification of the facility to Voluntary Action Indicated
Lupin Diagnostics will provide a comprehensive range of diagnostic tests. These include molecular diagnostics, cytogenetics, flow cytometry, microbiology, serology, histopathology and cytology, haematology, immunology, amongst others.
While industry steps out of its comfort zone to innovate, the government has to support by allocating funds across research lifecycle and offer incentives for innovation
According to WHO, over 1.5 million people died of TB in 2020
The profits were bolstered by the Boehringer Ingelheim MEK program income
Pegfilgrastim has estimated annual sales of USD 3.66 billion in the U.S. (IQVIA MAT December 2020).
It reported total income of Rs.15299.25 crores during the FY ended March 31, 2021
Reflecting on the learning during the pandemic, industry is aiming to push innovation in R&D and implement automation and digital technologies across various operational levels.
While top industry leaders are optimistic about the growth, they expect the special incentives and regulatory streamlining from the government’s side
Subscribe To Our Newsletter & Stay Updated
